MoneyWorks4Me

Biocon informs about disclosure

24 Dec 2024 Evaluate
Biocon has informed that the Company and it European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza® to treat Type-2 Diabetes and Saxenda® used in the treatment of weight management. The above information will also be available on the website of the Company at www.biocon.com. 

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..